Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial

BACKGROUND: With the emergence of SARS-CoV-2 variants resistant to monoclonal antibody therapies and limited global access to therapeutics, the evaluation of novel therapeutics to prevent progression to severe COVID-19 remains a critical need. METHODS: Safety, clinical and antiviral efficacy of inha...

Descripción completa

Detalles Bibliográficos
Autores principales: Jagannathan, Prasanna, Chew, Kara W., Giganti, Mark J., Hughes, Michael D., Moser, Carlee, Main, Mark J., Monk, Phillip D., Javan, Arzhang Cyrus, Li, Jonathan Z., Fletcher, Courtney V., McCarthy, Caitlyn, Wohl, David A., Daar, Eric S., Eron, Joseph J., Currier, Judith S., Singh, Upinder, Smith, Davey M., Fischer, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579289/
https://www.ncbi.nlm.nih.gov/pubmed/37855026
http://dx.doi.org/10.1016/j.eclinm.2023.102250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579289/
https://www.ncbi.nlm.nih.gov/pubmed/37855026
http://dx.doi.org/10.1016/j.eclinm.2023.102250

Ejemplares similares